Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15
Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15
巴克萊將Relay Therapeutics上調至增持,將目標股價維持在15美元
Barclays analyst Peter Lawson upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and maintains the price target from $15 to $15.
巴克萊分析師彼得·勞森將Relay Therapeutics(納斯達克股票代碼:RLAY)從等重上調至增持,並將目標股價從15美元維持至15美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。